Insulin Receptor Tyrosine Kinase Substrate Enhances Low Levels of MDM2-Mediated p53 Ubiquitination

Ke-Sheng Wang1, Gang Chen1,2, Hai-Lian Shen1, Ting-Ting Li1,2, Fei Chen1, Qin-Wan Wang1, Zhi-Qin Wang1, Ze-Guang Han1,3, Xin Zhang1*

1 Shanghai-MOST Key Laboratory for Disease and Health Genomics, Chinese National Human Genome Center at Shanghai, Shanghai, China, 2 School of Bioengineering, East China University of Science and Technology, Shanghai, China, 3 Rui-Jin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

Abstract

The tumor suppressor p53 controls multiple cellular functions including DNA repair, cell cycle arrest and apoptosis. MDM2-mediated p53 ubiquitination affects both degradation and cytoplasmic localization of p53. Several cofactors are known to modulate MDM2-mediated p53 ubiquitination and proteasomal degradation. Here we show that IRTKS, a novel IRSp53-like protein inhibited p53-induced apoptosis and depressed its transcription activity. IRTKS bound directly to p53 and increased p53 ubiquitination and cytoplasmic localization. Further studies revealed that IRTKS interacted with MDM2 and promoted low levels of MDM2-mediated p53 ubiquitination in vitro and in vivo. In unstressed cells with low levels of MDM2, IRTKS was found to stabilize the interaction of p53 and MDM2. In stressed cells, IRTKS dissociated from p53, and high levels of MDM2 induced by p53 activation mediate IRTKS poly-ubiquitination and subsequent proteasomal degradation. These data suggest that IRTKS is a novel regulator of p53, modulating low level of MDM2-mediated p53 ubiquitination in unstressed cells.

Introduction

The activity of p53 is controlled by a complicated network during normal homeostasis and stress response [1]. Multiple post-translational modifications of p53, including phosphorylation, acetylation, methylation, glycosylation, ubiquitination and ubiquitin-like modification, have been documented for p53 regulation [2,3]. Among these modifications, ubiquitination plays a pivotal role in controlling p53 activity under different conditions [4].

Ubiquitin conjugates to proteins either in a monomeric manner (monoubiquitination) to cause conformational change to the substrate or in a polyubiquitin chain which signals the substrate to be degraded by the 26S proteasome. While polyubiquitination serves as a signal for proteasomal degradation which requires an at least four-subunit-long mult ubiquitin chain per individual lysine residue, monoubiquitination has been shown to be involved in a variety of cellular processes, including protein trafficking, DNA repair and transcriptional regulation [5,6]. MDM2, a key regulator of p53, catalyzes both monoubiquitination and polyubiquitination on p53 in a dose-dependent manner. High levels of MDM2 mediate p53 polyubiquitination and proteasomal degradation, whereas low levels of MDM2 inhibit the monoubiquitination and nuclear export of p53 [7]. Some cofactors, including L5, L11, L23, p300/CPB, Yin Yang 1, MDMX, UBE4B, have been characterized to regulate MDM2-mediated ubiquitination and degradation [8,9]. But the regulation of low levels of MDM2-mediated p53 monoubiquitination and cytoplasmic translocation has been rarely reported.

IRSp53-like proteins contain a conserved IRSp53/MIM homology domain (IMD) at the N-terminus, and a canonical SH3 domain near the C-terminus [10]. The IMD belongs to the larger family of Bin-amphipysin-Rvs67 (BAR) domains that can bundle actin filaments and induce membrane protrusions [11]. The IRSp53 family is involved in the formation of filopodia and lamellipodia [12]. Insulin receptor tyrosine kinase substrate (IRTKS), an IRSp53-like protein, has been recognized as a substrate for the insulin receptor tyrosine kinase and its overexpression induces clustering of short actin bundles [13]. However, IRTKS is largely localized in the nucleus wherein its function remains unknown.

In this study, we first found that IRTKS suppressed the p53 induced apoptosis and transactivation activity. IRTKS interacted directly with both p53 and MDM2 through its IMD domain, and enhances low level MDM2-mediated p53 ubiquitination in vitro and in vitro. Interestingly, the effect of IRTKS on the p53-MDM2 axis is dependent on the protein levels of MDM2. At normal physiological status, the interaction between p53 and low level MDM2 was enhanced by IRTKS. During stress, p53 dissociated with IRTKS. And high levels of MDM2 induce ubiquitin-mediated degradation of IRTKS. These data together suggested that the scaffold protein, IRTKS may balance the MDM2 activity in mediating p53 ubiquitination.

Results

IRTKS suppressed p53-induced apoptosis and negatively regulated the transcription activity of p53

To investigate the function of IRTKS, we established a stable HT1080 cell line (HT1080-IRTKS) with expressing ectopic FLAG-tagged IRTKS upon withdrawal of doxycycline [14]. Interestingly, overexpression of IRTKS remarkably suppressed...
serum depletion-induced cell death (Figure 1A), implying that IRTKS may possess anti-apoptotic activity. HT1080 cells express wild type p53, which mediates the apoptotic response to DNA damage [15]. We found that IRTKS overexpression reduced the number of apoptotic cells upon UV exposure (Figure 1B and Figure S1A). By contrast, IRTKS depletion by RNA interference (RNAi) enhanced UV irradiation-induced apoptosis (Figure 1C and Figure S1B) and the apoptosis-related cleavage of poly(ADP-ribose) polymerase (PARP) (Figure S1C). We also infected p53-null SOAS-2 cells with adenoviruses expressing p53 and IRTKS, and found that IRTKS overexpression inhibited apoptosis mediated by ectopic p53 (Figure 1D and Figure S1D) while IRTKS knockdown increased p53-induced apoptosis in SOAS-2 cells (Figure 1E and Figure S1E). These observations demonstrated that IRTKS negatively modulated p53-induced apoptosis.

p53-induced apoptosis is largely dependent on its transactivation of such proapoptotic genes as BAX, PUMA and PIG3 [16–18]. We sought to determine the effect of IRTKS induction on the expression of p53 target genes. We found that IRTKS overexpression slightly decreased the expression of PIG3 and MDM2 in SOAS-2 cells (Figure 1D, right panel). By contrast, deletion of IRTKS increased the expression of PIG3 and MDM2 in SOAS-2 cells (Figure 1E, right panel). Induction of IRTKS overexpression in HT1080 cells upon doxycycline withdrawal also reduced the levels of PIG3, PUMA and MDM2 with no apparent effect on the expression of p53 (Figure 1F). Furthermore, in SOAS-2 cells, using a luciferase reporter system under the control of the BAX promoter, we found that IRTKS overexpression dose-dependently inhibited p53-induced luciferase activity (Figure 1G). These data showed that IRTKS attenuated the transactivation of p53 on its downstream genes, suggesting that IRTKS may exert its anti-apoptotic effect through modulating p53 transactivation activity.

**IRTKS interacted directly with p53 in nucleus**

We were interested in determining whether IRTKS exerted its effects on p53 through its physical association with the protein. We defined the subcellular localization of both proteins by immunofluorescence assays, which showed that both IRTKS and p53 were co-localized in the nucleus (Figure 2A), suggesting that IRTKS could physically associate with p53. Reciprocal co-immunoprecipitations (Co-IPs) using antibodies against IRTKS and p53 confirmed their association in HEK 293 and HT1080 cells (Figure 2B, Figure S2A). Co-IPs with nuclear and cytoplasmic extracts from HT1080 cells further revealed that, consistent with the data from immunofluorescence assays (Figure 2A), endogenous IRTKS interacted with p53 exclusively in the nucleus (Figure 2C). Direct interaction of IRTKS with p53 was further demonstrated in vitro by GST-pulldown assays (Figure 2D). Additionally, two regions of IRTKS (N-terminal 1–250 and 250–350 amino acid residues), which contain the IMD domain and an uncharacterized domain, respectively, were found to interact with p53 by GST-pulldown experiments with a series of deletion variants of IRTKS (Figure 2D). Consistently, two regions of p53 were involved in the direct interaction of IRTKS and p53. While the p53 deletion variants containing its C-terminal regulatory domain (CRD) strongly bound to IRTKS, the DNA binding domain (DBD) of p53 also interacted with IRTKS (Figure 2E and Figure S2B). These findings indicated that IRTKS physically associated with p53 in the nucleus via their functional domains.

**IRTKS increases the ubiquitination and the cytoplasmic localization of p53**

p53 can be negatively regulated at the transcriptional, translational and post-translational levels [1]. As IRTKS did not alter the abundance of p53 mRNA and protein levels (Figure 1F and Figure S3), we proposed that IRTKS negatively modulated p53 activity at the post-transcriptional level. We found that IRTKS overexpression failed to induce changes in phosphorylation and acetylation of certain amino acid residues of p53 under stress or unstress conditions, including serine 15, 20, 37, 46, 392, and lysine 382 (Figure S3). However, p53 ubiquitination with lower molecular weights (<130 Kd) was significantly increased in HT1080 cells overexpressing IRTKS (Figure S4A). By contrast, IRTKS knockdown reduced the ubiquitination of endogenous p53 (Figure S4B). In vivo ubiquitination assay in U2OS cells further confirmed that, distinct from the p53 ubiquitination pattern by ectopic MDM2, IRTKS indeed mediated p53 ubiquitination with increasing lower molecular weight modifications (Figure 3A).

Previous reports have demonstrated that p53 polyubiquitination is associated with its proteasomal degradation while p53 mono-ubiquitination induces its nuclear export. Our data here showed that IRTKS did not affect the protein levels of endogenous and ectopic p53 (Figure S3 and S4; Figure 1D and 1E). On the contrary, IRTKS overexpression slightly stabilized endogenous p53 in U2OS cells treated with cycloheximide (Figure 3B). Our immunofluorescence assay revealed that IRTKS overexpression increased the cytoplasmic localization of p53 (Figure 3C). These data indicated that IRTKS-induced p53 ubiquitination affects the subcellular localization of p53.

**IRTKS interacts with MDM2**

IRTKS was previously considered as a scaffold protein without enzymatic activity [13,19]. IRTKS alone also failed to demonstrate any catalytic activity on p53 ubiquitination in our in vitro ubiquitination assays (Figure S6B, lane 1–4). Therefore, IRTKS might function as an adaptor for the ubiquitin E3 ligases to mediate p53 ubiquitination. As known, MDM2 is essential for regulating p53 function and catalyzes p53 ubiquitination for degradation and nuclear export dose-dependently [7,20,21]. In MDM2 null cells, IRTKS only increased p53 ubiquitination when MDM2 was co-transfected to the cells (Figure S5), implying that IRTKS affected MDM2-mediated p53 ubiquitination (Figure S5). To assess the possibility that IRTKS could serve as an adaptor of MDM2, we performed MDM2 and IRTKS co-localization assays, which disclosed an almost identical subcellular localization of IRTKS and MDM2, especially in the nucleus (Figure 4A). Co-IP analysis additionally revealed that endogenous IRTKS and MDM2 were reciprocally immunoprecipitated (Figure 4B), suggesting that IRTKS indeed physically associated with MDM2. In vitro GST-pulldown assays with purified recombinant proteins confirmed their physical interaction, where both the IMD domain of IRTKS and 150–300 residues of MDM2 were required for their interaction (Figure 4C and 4D). These data implied that IRTKS could recruit both MDM2 and its substrate p53 through the IMD domain and serve as a cofactor of MDM2.

**IRTKS promoted p53 ubiquitination induced by low levels of MDM2**

We further explored the role of IRTKS in MDM2-mediated p53 ubiquitination by assessing the activity of MDM2 for p53 ubiquitination using in vitro ubiquitination assays with recombinant MDM2 and p53. Consistent with the previous study [7], MDM2 induced p53 monoubiquitination and polyubiquitination dose-dependently (Figure S6A). Using this ubiquitination system, we found that IRTKS only enhanced low molecular weight of p53 ubiquitination (<?130 Kd) mediated by low levels of MDM2, but had no effect on p53 ubiquitination induced by high levels of MDM2 (Figure 5A). Moreover, IRTKS variant with IMD deletion
Figure 1. IRTKS suppressed p53-induced apoptosis and transactivation activity. (A) IRTKS inhibited cell death triggered by serum starvation. The IRTKS Tet-off HT1080 cells were cultured in serum-free medium in the presence or absence of doxycycline (DOX, 10 ng/ml). The cells were harvested at days 1, 2, 3, and 4 for apoptosis analysis. (B) IRTKS suppressed UV-induced apoptosis. The MOCK, UV, IRTKS, and FLAG-IRTKS were transfected into HT1080 cells and exposed to UV radiation for 24 hours. The cells were harvested and apoptosis was analyzed. (C) IRTKS regulated MDM2-mediated p53 ubiquitination. The siIRTKSm and siIRTKS were transfected into HT1080 cells and the levels of IRTKS and actin were analyzed. (D) IRTKS suppressed p53-induced apoptosis. The MOCK, IRTKS, p53, PIG3, MDM2, and IRTKS were transfected into HT1080 cells and apoptosis was analyzed. (E) IRTKS regulated BAX expression. The GFP and p53 were transfected into HT1080 cells and BAX expression was analyzed.

---

**Note:** The above text describes the experiment and results shown in the figures. The figures illustrate the effects of IRTKS on apoptosis and transactivation activity in HT1080 cells under different conditions.
failed to enhance MDM2-induced p53 ubiquitination (Figure 5B), indicating that the IMD region which was required for the physical association of IRTKS with both MDM2 and p53, was crucial for IRTKS-induced p53 ubiquitination.

In vivo ubiquitination assays using H1299 cells also revealed that IRTKS promoted p53 ubiquitination only with low levels of MDM2 (Figure 5C, lane 4 compared with lane 2). It has been reported that MDM2 mediates both ubiquitination and neddylation of p53. MDM2-mediated NEDD8 modification inhibits p53 transcription activity [22]. Herein, in vivo neddylation assay showed that IRTKS overexpression could not alter MDM2-mediated neddylation of p53 (Figure 5D). Therefore, as a cofactor of MDM2, IRTKS only enhanced p53 ubiquitination induced by low level MDM2.

IRTKS enhanced the p53-MDM2 interaction at low levels of MDM2

Previous studies showed that the N terminal regions of both MDM2 and p53 provide the primary site for their physical interactions [23], which are distinct from the domain that mediated their binding to IRTKS shown here. Our data indicated that the IMD domain was required for IRTKS binding to p53 and MDM2 and for its effect on MDM2-mediated p53 ubiquitination. The crystal structure of IRTKS indicates that IMD could self-associate into an 180 Å-long zeppelin-shaped dimer [11,24]. Moreover, an uncharacterized domain of the middle region of IRTKS could provide a secondary site for interaction with p53. These observations raised the intriguing possibility that IRTKS could affect the p53-MDM2 interaction in vivo. Co-IP assays revealed that endogenous p53, MDM2 and IRTKS were all immunoprecipitated with antibodies against p53 or MDM2 (Figure 6A), suggesting that they were present in the same protein complex. We then evaluated the effect of IRTKS on the interaction between MDM2 and p53. Interestingly, a cotransfection experiment in H1299 cells showed that the interaction between MDM2 and p53 was significantly enhanced by ectopic IRTKS with low levels of MDM2 (Figure 6B, lane 4 compared with lane 3), whereas no effect on the association of high levels of MDM2 with p53 was detected (Figure 6B, lanes 5 and 6). Additionally, consistent with our findings in vitro and in vivo ubiquitination assays, p53 ubiquitination at low molecular (<130 kDa) was increased at low levels of MDM2 with IRTKS overexpression (Figure 6B, lane 4 compared with lane 3). In contrast, IRTKS knockdown attenuated the p53-MDM2 interaction and p53 ubiquitination at low levels, not high levels, of MDM2 (Figure 6C). These data together indicated that IRTKS induced p53 ubiquitination through enhancing the interaction between p53 and low levels of MDM2 in unstressed cells.

MDM2 is an E3 ubiquitin ligase for IRTKS degradation

The protein levels of IRTKS were significantly decreased after DNA damage in HT1080 cells (Figure S1B and Figure 7A) but not in p53-null SAOS-2 cells (Figure S7A), suggesting that IRTKS could be decrease by DNA damage induced p53 activation. This finding promoted us to assess the dynamics of IRTKS expression. Interestingly, MDM2 overexpression reduced the protein levels of IRTKS (Figure 7B), suggesting that MDM2 may mediate IRTKS degradation. Both in vitro and in vivo ubiquitination assays demonstrated that MDM2 mediated IRTKS ubiquitination in a dose-dependent manner (Figure 7C and 7D). These results strongly indicated that MDM2 as an E3 ubiquitin ligase affected IRTKS stability at high activity levels via ubiquitination and proteasomal degradation.

We then investigated the effect of DNA damage on the interaction of IRTKS, p53 and MDM2. UV irradiation in HT1080 cells significantly attenuated the interaction between endogenous IRTKS and p53 (Figure S7B). Moreover, the DNA-damaging agent etoposide abolished the IRTKS-p53 interaction and stabilized the IRTKS-MDM2 interaction in U2OS cells when all three proteins were stabilized by MG132 (Figure 7E). These data suggested that DNA damages affected the IRTKS-p53 and IRTKS-MDM2 interactions differently and specifically.

Discussion

P53-induced transcriptional alteration causes a variety of cell fate changes, including apoptosis, growth arrest, senescence, DNA repair. For maintenance the homeostasis of cell, various processes are equipped to modulate p53 activity. Adjusting the protein levels and transcriptional activity of p53 are two essential processes for cells to maintain the physiological state [25]. Although polyubiquitination of p53 targets its proteasomal degradation, several studies have demonstrated that p53 ubiquitination also affects its activation. WWP1-mediated p53 ubiquitination causes stabilization of p53 but inactivates p53 transactivation [26]. UbCl3 elicits K63-dependent ubiquitination of p53, increases p53 localization to the cytoplasm and p53 stability, and decreases its transcriptional activity [27]. CUL7 causes only mono- or di-ubiquitination of p53, and promotes cell growth through antagonizing the function of p53 [28]. p53 ubiquitination could be important for keeping p53 inactive. De-ubiquitination of p33 is essential for p53-mediated mitochondrial apoptosis and for recycling of p53 from cytoplasm to nucleus [21,29]. In this study, our data showed that IRTKS decreased p53 activity and increased low levels of MDM2-mediated p53 ubiquitination via binding to both p53 and MDM2. How, then, IRTKS promoted MDM2-mediated p53 ubiquitination but not degradation via direct interaction? N-terminal transactivation domain of p33 has been characterized as the
IRTKS Regulates MDM2-Mediated p53 Ubiquitination

A. DAPI staining and IRTKS localization.

B. Immunoprecipitation (IP) analysis showing IRTKS and p53 interactions.

C. Western blot analysis of IRTKS and p53 expression levels under control (CE) and nuclear extract (NE) conditions.

D. GST-IRTKS pull-down assay showing the binding to p53 epitopes.

E. GST-p53 pull-down assay showing the binding to IRTKS epitopes.
primary binding site to MDM2 [23,30,31]. This primary interaction has been documented to be essential, but not sufficient, to target p53 degradation. The second binding site of p53 to MDM2 has been identified in its DNA-binding domain [32,33]. A conformational change of MDM2 caused by the primary interaction enables binding of the central region in MDM2 to the DNA-binding domain of p53 [34]. The secondary interaction is required for efficient p53 polyubiquitination and proteasomal degradation [35]. p53 mutants which contain single point mutations in p53 DNA binding domain have increased levels of MDM2-dependent ubiquitination, but not degradation of p53 in vivo [36]. Similarly, IRTKS slightly stabilized p53 protein while increased p53 ubiquitination (Figure 3B), implying that the binding of IRTKS and p53 affected the secondary interaction of p53 and MDM2.

Several partners of MDM2, including ARF, L5, L11, and L23, have been reported to bind to the central region of MDM2 [37–41]. Most of them inhibit MDM2-mediated p53 ubiquitination and degradation, probably by blocking the secondary interaction between MDM2 and p53. Our data suggest that IRTKS bound to both the central domain of MDM2 and the DNA binding domain of p53, and recruited MDM2 to p53 in unstressed cells. IRTKS stabilized the p53-MDM2 interaction at low levels of MDM2, but it could also block the secondary interaction sites of p53-MDM2 interaction. Therefore, IRTKS enhanced p53 ubiquitination but not degradation in unstressed cells.

![Figure 2. IRTKS directly interacted with p53.](image-url)

![Figure 3. IRTKS enhanced the ubiquitination and cytoplasmic localization of p53.](image-url)
The effects of MDM2-mediated ubiquitination on p53 are in a delicate balance to determine the cell fate during normal homeostasis and stress response. The negative feedback loop between MDM2 and p53 ensures that p53 is maintained at low levels under normal conditions or after stress resolved [4]. Interestingly, IRTKS could also be involved in the negative feedback regulation. Here we showed that p53 dissociated with IRTKS after DNA damage. IRTKS polyubiquitination and degradation by high levels of MDM2 might increase the direct interaction of the secondary sites of p53 and MDM2 for p53 polyubiquitination and degradation.

Together, these data led us to propose a novel mechanism for maintaining the balance of MDM2-mediated ubiquitination on p53 during normal homeostasis and stress response. In unstressed cells with low levels of MDM2, IRTKS stabilized the MDM2-p53 interaction and enhanced MDM2-mediated p53 ubiquitination, thereby inhibiting p53 transcriptional activity. In response to DNA damage, the stabilized MDM2-IRTKS dissociated from p53. MDM2 may possess E3 ligase for self-degradation and IRTKS ubiquitination. Late after DNA damage, MDM2, as a p53 target, was up-regulated and high levels of MDM2 mediated the polyubiquitination and degradation of both IRTKS and p53.

Several proteins have been proved to act as a regulator and substrate of MDM2 in the negative feedback regulation loop between p53 and MDM2. MDM2 can downregulate p53 protein synthesis by inducing the polyubiquitination of L26, a ribosomal protein which stimulates translation of p53 mRNA after DNA damage [42]. Another ribosomal protein S7 interacts with MDM2, inhibiting the E3 ligase activity of MDM2 and stabilizing both MDM2 and p53. S7 itself is ubiquitinated by MDM2 and ubiquitinated S7 selectively destabilizes MDM2, enhancing the p53 stress response [43]. Herein, we demonstrated IRTKS can regulate p53 by modulating the p53-MDM2 interaction as a scaffold protein and substrate of MDM2.

Previous studies suggest that IRSp53-like proteins, including IRTKS, contribute to actin dynamics and membrane protrusion. This function is mainly achieved by the IMD which is the most conserved domain of these proteins [12]. The IMD, also known as an I-BAR (inverse Bin-amphiphysin-Rvs167) domain, binds F-actin, RAC, and lipid, triggering protrusive membrane deformation [10]. Here we show that the IMD of IRTKS was responsible for its association with p53 and MDM2, indicating the IMD-contain proteins might have combination functions of cell mobility and apoptosis. This finding suggests that the IRSp53-like proteins...
IRTKS may have diverse functions in cytoplasm and nucleus. While the middle region of IRTKS is a partial CRIB domain which binds to active CDC42, IRTKS can not interact with CDC42 and its middle region provided a second binding site for IRTKS-p53 interaction. Therefore, it remains to determine whether the other IRSp53-like proteins can affect p53 ubiquitination. As a tumor suppressor, p53 is presumed as a protein that acts negatively to prevent motility and tumor metastasis [44]. Actin polymerization and membrane deformation are important processes for cell mobility [45]. Recently, a p53 cofactor JMY, has been identified as an actin nucleation factor which is involved in to cell motility [46]. Under DNA damage, JMY augments in nucleus and drives the p53 transcription, its influence on cell mobility is reduced [47]. As IRTKS was involved in both actin dynamic and p53 modification, it remains to investigate whether IRTKS is another protein for coordinating cell mobility with the p53 response. And further studies need to address the behavior of IRTKS in tumor as it has diverse functions in inhibiting p53 activation in nucleus and promoting cell mobility in cytoplasm.

**Materials and Methods**

**Plasmids and antibodies**

The entire open reading frame of human IRTKS was amplified from a human fetal liver cDNA library (Clontech) and subcloned into mammalian cell expression vectors pFLAG-CMV 2 (Sigma) for mammalian expression. Plasmids for expressing p53 and MDM2 in mammalian cells were constructed in pcDNA 3.0. For in vitro experiment, IRTKS, p53 and MDM2 including their truncations were constructed by PCR, and subcloned into pGEX-5X-1 and PET-28a. For immunoblotting and immunoprecipitation detection of endogenous IRTKS, a rabbit polyclonal antibody was raised against GST-IRTKS. p53 antibody DO-1 and FL393, MDM2 antibody H-221 (Santa Cruz) were used for immunoprecipitation. p53 antibody 1C12 (Cell Signaling Technology) and MDM2 antibody H-221 were used for immunofluorescence staining. p53 antibody DO-1 and FL393, MDM2 antibody H-221, cleaved PARP (Asp214) antibody (Cell Signaling Technology) and PIG3 antibody A-5 (Santa Cruz) were used for Western blotting.
Cell culture

Human HT1080, U2OS, SAOS-2, H1299 and HEK 293 cells (ATCC) were cultured at 37°C in DMEM supplemented with 10% fetal bovine serum (FBS). p53–Mdm2 double knockout mouse embryonic fibroblast cell line was kindly provided by Prof. Long Yu (Fudan University). Cells were transfected using FuGENE HD or FuGENE 6 by the manufacturer’s protocol (Roche). Short interfering RNA (siRNA) oligonucleotides were transfected into cells using Lipofectamine 2000 by the manufacturer’s instructions (Invitrogen). The IRTKS siRNA (siIRTKS) sequence was 5′-GCUUAAGCAAUCAGGUU-3′. The same sequence with two nucleotides changed (5′-GCUUGAGCAAUCAGGUU-3′) was used as a specific RNAi control (siIRTKSm). The p53 siRNA sequence was 5′-GACUCCAGUGGUAAUCUAC-3′ and MDM2 siRNA sequence was 5′-CCACCUCAAGAUUCACG-3′. Luciferase siRNA (5′-CUUACGCUGAGUACUUCG ATT-3′) was used as a control siRNA (siLUC).

Apoptosis assay

HT1080 cells transfected with FLAG-IRTKS or IRTKS siRNA were UV-irradiated (60 J/M²). The cell apoptosis was detected by using Annexin V-FITC apoptosis detection kit (Pharmingen) according to the manufacturer’s instructions (Invitrogen). The IRTKS siRNA (siIRTKS) sequence was 5′-GCUUAAGCAAUCAGGUU-3′. The same sequence with two nucleotides changed (5′-GCUUGAGCAAUCAGGUU-3′) was used as a specific RNAi control (siIRTKSm). The p53 siRNA sequence was 5′-GACUCCAGUGGUAAUCUAC-3′ and MDM2 siRNA sequence was 5′-CCACCUCAAGAUUCACG-3′. Luciferase siRNA (5′-CUUACGCUGAGUACUUCG ATT-3′) was used as a control siRNA (siLUC).

Immunofluorescence microscopy

Cells cultured on coverslips were washed twice with cold PBS. Cells were fixed with 4% paraformaldehyde for 10 min, permeabilized with 0.1% Triton X-100 for 10 min, blocked with 5% bovine serum albumin (BSA) and incubated with anti-IRTKS and anti-p53 or anti-MDM2 antibodies as indicated, followed by incubation with Alexa-546 conjugated anti-rabbit IgG and Alexa-488 conjugated anti-mouse IgG antibody (Invitrogen). The cells were mounted with DAPI-containing medium (Sigma) and the images were acquired with a confocal microscope.

Immunoprecipitation and Western blotting

Whole cell lysates were prepared in the lysis buffer (50 mM Tris at pH 8.0, 150 mM NaCl, 1% Triton X-100, 1 x complete protease cocktail, 5 mM sodium vanadate, and 10% glycerol). The lysates were then immunoprecipitated with the indicated antibodies and isotype-matched control antibodies plus protein G Sepharose (Roche) for at least 4 h or overnight. Beads were washed three times with the lysis buffer, and boiled in 2 x loading buffer. Protein samples were resolved by SDS–PAGE and transferred onto nitrocellulose membrane, which was blocked in 5% skim milk in PBS-Tween and probed with the indicated antibodies. The membrane was scanned by Odyssey infrared imaging system (LI-COR) at a 700–800 channel wavelength.

Subcellular fractionation

Nuclear and cytoplasmic fractions were prepared using NE-PER® Nuclear and Cytoplasmic Extraction Reagents (Pierce biotechnology) according to the manufacturers’ protocol. Purity of fractions was determined by western blotting with anti-HDAC1 and anti-Tubulin (Santa Cruz Biotechnology) antibodies.

In vivo ubiquitination and neddylation assay

Cells were transfected with His-ubiquitin, HA-ubiquitin or HA-NEDD8 and other indicated plasmids. Twenty hours after transfection, cells were treated with 25 μM MG132 for 4–6 h and scraped into PBS and pelleted by centrifugation. For transfections with His-ubiquitination, cells were resuspended in 1 ml of...
denaturing buffer (6 M guanidinium-HCl, 0.5% Triton, 10 mM imidazole, 20 mM Tris-HCl [pH 8], 0.5 mM DTT, and 0.5 mM iodoacetamide) with mild sonication. His–Ub conjugated proteins were purified by nickel chromatography (Ni-NTA Agarose; Qiagen). Nickel bound ubiquitinated proteins were subjected to Western blotting analysis using anti-p53 Ab (DO-1). For transfections with HA-ubiquitin or HA-NEDD8, cells were resuspended in 1% SDS in TBS and boiled twice for 5 min each time. The lysates were diluted to a solution with final concentrations of 0.2% SDS and 1% Triton X-100, and immunoprecipitated with anti-HA antibody (Sigma). The ubiquitinated or neddylated proteins were analyzed with Western blotting by using anti-p53 Ab (DO-1).

In vitro ubiquitination assay

Purified recombinant proteins as indicated were incubated in 20 µl of reaction buffer (50 mM Tris-HCl pH 7.6, 1 mM DTT, 2 mM ATP and 5 mM MgCl2), in the presence of 50 ng of E1 and 100 ng E2 (Ubch5a) enzymes and 10 µg of ubiquitin (Boston Biochem, Boston, MS). After incubation at 32°C for 1 h, the reaction products were analyzed by SDS-PAGE followed by Western blotting.

Supporting Information

Figure S1 IRTKS inhibited apoptosis. (A) Overexpression of IRTKS inhibited UV-induced apoptosis. HT1080 cells were transfected with pCMV-FLAG-IRTKS for overexpression of IRTKS, UV-irradiated (60 J/M2) and analysed by FACS with Annexin V FITC/PI staining. For evaluation of cells undergoing apoptosis, cells were stained by both Annexin V-FITC and PI, and the PI-positive cells were excluded from the measurement. (B) Knockdown of IRTKS enhanced UV-induced apoptosis in HT1080 cells. HT1080 cells were transfected with IRTKS siRNA and control siRNA, UV-irradiated and analysed by FACS with Annexin V FITC/PI staining. (C) HT1080 cells were transfected with IRTKS siRNA and control siRNA, UV-irradiated and analysed with anti-cleaved PARP, anti-p53 and anti-IRTKS by Western blotting at indicated time points. Note that the cleaved PARP was increased earlier in the cells with IRTKS knockdown and IRTKS was decreased after UV irradiation. (D) Overexpression of IRTKS reduced the apoptosis induced by p53. SAOS-2 cells were examined by phase contrast microscopy after infection with Ad-p53, Ad-IRTKS and control virus: AdGFP, for 48 h. (E) Knockdown of IRTKS increased the apoptosis induced by p53. (TIF)
**Figure S2** IRTKS interacted with p53. (A) HT1080 cells were pretreated with the proteasome inhibitor MG132. The endogenous interaction of IRTKS and p53 was analyzed by immunoprecipitation assay with anti-p53 antibody. (B) The fine-mapping of the interaction sites of p53 binding to IRTKS by GST-pulldown assays. (TIF)

**Figure S3** IRTKS could not affect the phosphorylation and acetylation of certain amino acid residues of p53. (A) The effect of IRTKS overexpression on p53 phosphorylation. HT1080 cells transfected with IRTKS or control plasmid were untreated, UV-irradiated (60 J/M²) or treated with doxorubicin (DOX, 1 µM) for 20 h and collected in lysis buffer. The cell lysates were immunoprecipitated [IP] with anti-p53 antibodies and analyzed by Western blotting using anti-phospho-p53 (S15, S37, S46) and anti-p53 antibodies. (B) The effect of IRTKS depletion on p53 phosphorylation. HT1080 cells transfected with IRTKS siRNA were treated with UV irradiation and harvested at indicated time. p53 phosphorylation were analyzed by Western blotting using anti-phospho-p53 (S15, S20 and S392), (C) and (D) HT1080 cells with overexpression (C) or knockdown (D) of IRTKS were UV-irradiated for 20 hr. The cells treated with trichostatin A (10 nM) for 4 hr and collected in lysis buffer. The cell lysates were immunoprecipitated [IP] with anti-p53 antibodies and analyzed by Western blotting using anti-acetyl-p53 (K392) and anti-p53 antibodies. (TIF)

**Figure S4** IRTKS enhanced p53 ubiquitination. (A) IRTKS enhanced ubiquitination of endogenous p53. HT1080 cells transfected with IRTKS or control plasmid were untreated, UV-irradiated (60 J/M²) or treated with doxorubicin (DOX, 1 µM) for 20 h. The cell lysates were loaded on nickel (Ni⁺-NTA) columns. p53 ubiquitination without MDM2 expression. The cell lysates were immunoprecipitated with anti-p53 antibody (DO-1). Note that IRTKS could not increase p53 ubiquitination without MDM2 expression. (B) In vitro ubiquitination experiments show that IRTKS promoted p53 ubiquitination mediated by MDM2. (TIF)

**Figure S5** p53–Mdm2 double knockout mouse embryonic fibroblasts were transfected with indicated plasmids. The cell lysates were loaded on nickel (Ni⁺-NTA) columns. p53 ubiquitination was analyzed with Western blotting with using anti-p53 antibody (DO-1). Note that IRTKS cloud not increase p53 ubiquitination without MDM2 expression. (TIF)

**Figure S6** IRTKS promoted MDM2-mediated p53 ubiquitination. (A) MDM2 induced both mono- and poly-ubiquitination of p53 in a dose-dependent manner in vitro. Western blotting analysis with p53-specific monoclonal antibody (DO-1) of p53 (100 ng) incubated with varying amounts of His-MDM2. (B) In vitro ubiquitination experiments show that IRTKS promoted p53 ubiquitination mediated by MDM2. (TIF)

**Figure S7** MDM2 mediated IRTKS degradation. (A) DNA damage could not alter the protein levels of IRTKS in SAOS-2 cell. (B) DNA damage disrupted the IRTKS-p53 interaction. HT1080 cells were exposed to UV radiation (60 J/ M²) and lysed at the indicate time. The cell lysates were immunoprecipitated with p53 antibody. The association of IRTKS and p53 was detected by Western blotting. (TIF)

**Acknowledgments**

We thank X. Zheng (Shanghai Jiao Tong University) for pTet-splice and pTet-Tak plasmids. We also thank L. Yu (Fudan University) for technical support on this work.

**Author Contributions**

Conceived and designed the experiments: K-SW GC H-LS T-TL Q-WW FC. Wrote the paper: XZ.

**References**

1. Kruse JP, Gu W (2009) Modes of p53 regulation. Cell 137: 609–622.
2. Bode AM, Dong Z (2004) Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 4: 795–805.
3. Kruse JP, Gu W (2008) SnapShot: p33 posttranslational modifications. Cell 133: 930–930 e931.
4. Brooks CL, Gu W (2006) p53 ubiquitination: Mdm2 and beyond. Mol Cell 21: 307–315.
5. Sugiymund S, Polo S, Di Fiore PP (2004) Signaling through monoubiquitination. Curr Top Microbiol Immunol 296: 149–185.
6. Thrower JS, Hoffman L, Rechtsteiner M, Pickart CM (2000) Recognition of the polyubiquitin proteolytic signal. EMBO J 19: 94–102.
7. Li M, Brooks CL, Wu-Baer F, Chen D, Bae R, et al. (2005) Mono- versus polyubiquitination: differential control of p53 fate by Mdm2. Science 302: 1972-1973.
8. Coutts AS, Adams CJ, La Thangue NB (2009) p53 ubiquitination by Mdm2: a never ending tail? DNA Repair (Amst) 8: 483–490.
9. Wu H, Pomeroy SL, Ferreira M, Teider N, Mariani J, et al. (2011) UBE4B contributes to early cellular response to DNA damage. Oncogene 30: 3743–3751.
10. Scita G, Confalonieri S, Lappalainen P, Suetsugu S (2008) IRSp53: crossing the road of membrane and actin dynamics in the formation of membrane protrusions. Trends Cell Biol 18: 54–60.
11. Millard TH, Bompad G, Heung MY, Dafton TR, Scott DJ, et al. (2005) Structural basis of filopodia formation induced by the IRSp53/MM family homology domain of human IRTKS. EMBO J 24: 240–250.
12. Yamagishi A, Masuda M, Ohki T, Onishi H, Mochizuki N (2004) A novel actin bundling/filopodium-forming domain conserved in insulin receptor tyrosine kinase substrate p53 and missing in metastasis protein. J Biol Chem 279: 14929–14936.
13. Millard TH, Dawson J, Machens LM (2007) Characterisation of IRTKS, a novel IRSp53/MM family actin regulator with distinct filament bundling properties. J Cell Sci 120: 1663–1672.
14. Lee J, Cheng Z, Wang K, Chen F, Han Z, et al. (2009) Cloning and expressing of IRTKS and its effect on cell morphology. J Med Mol Biol 6: 214–218.
15. Grezzi O, Karuman P, Jones DR, Kuzem D, Cha J, et al. (2003) The PHD finger of the chromatin-associated protein ING2 functions as a nuclear phosphoinositide receptor. Cell 114: 99–111.
16. Zhan Q, Fan S, Bae I, Guillouf G, Liebermann DA, et al. (1994) Induction of apoptosis on this work.
17. Nakano K, Vouenlid K (2001) PUMA, a novel prosapoptotic gene, is induced by p53. Mol Cell 7: 693–694.
18. Lee JH, Kang Y, Khare V, Jin ZY, et al. (2010) The p53-induced gene 3 (PIG3) contributes to early cellular response to DNA damage. Oncogene 29: 1431–1430.
19. Saarikangas J, Zhao H, Pykalainen A, Laurimaki P, Matulla PK, et al. (2009) Molecular membranes of membrane deformation by I-BAR domain proteins. Curr Biol 19: 95–107.
20. Carter S, Bischof O, Dejean A, Vouenlid K (2007) C-terminal modifications regulate MDM2 dissociation and nuclear export of p53. Nat Cell Biol 9: 428–435.
21. Marchenko ND, Wolff S, Erster S, Becker K, Moll UM (2007) Mono- versus polyubiquitination: differential control of p53 fate by Mdm2. Science 302: 1972-1973.
22. Xirodimas DP, Saville MK, Bourdon JC, Hay RT, Lane DP (2004) Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity. Cell 118: 83–97.
23. Chen J, Marechal V, Levine AJ (1993) Mapping of the p53 and mdm-2 interaction domains. Mol Cell Biol 13: 4107–4114.
24. Suetsugu S, Murayama K, Sakamoto A, Hanawa-Suetsugu K, Seto A, Oikawa T, et al. (2006) The RAC binding domain/IRSp53-MIM homology domain of IRSp53 induces RAC-dependent membrane deformation. J Biol Chem 281: 35347–35358.
25. Levine AJ, Oren M (2009) The first 30 years of p53: growing ever more complex. Nat Rev Cancer 9: 749–750.
26. Laine A, Ronai Z (2007) Regulation of p53 localization and transcription by the HECT domain E3 ligase WWP1. Oncogene 26: 1477–1483.
27. Andrews P, He YJ, Xiong Y (2006) Cytoplasmic localized ubiquitin ligase cullin 7 binds to p53 and promotes cell growth by antagonizing p53 function. Oncogene 25: 4534–4548.
28. Yuan J, Lao K, Zhang L, Cheville JC, Lou Z (2010) USP10 regulates p53 localization and stability by deubiquitinating p53. Cell 140: 384–396.
29. Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J, et al. (1996) Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274: 948–953.
30. Sakaguchi K, Saito S, Higashimoto Y, Roy S, Anderson CW, et al. (2000) Damage-mediated phosphorylation of human p53 threonine 18 through a cascade mediated by a casein 1-like kinase. Effect on Mdm2 binding. J Biol Chem 275: 9278–9283.
31. Ma J, Martin JD, Zhang H, Auger KR, Ho TF, et al. (2006) A second p53 binding site in the central domain of Mdm2 is essential for p53 ubiquitination. Biochemistry 45: 9258–9265.
32. Yu GW, Rodger S, Verpinnev D, Freund S, Fernandez-Fernandez MR, et al. (2006) The central region of HDM2 provides a second binding site for p53. Proc Natl Acad Sci U S A 103: 1227–1232.
33. Wallace M, Worrall E, Pettersson S, Hupp TR, Ball KL (2006) Dual-site regulation of MDM2 E3-ubiquitin ligase activity. Mol Cell 23: 251–263.
34. Argentini M, Barboule N, Wasylyk B (2001) The contribution of the acidic domain of MDM2 to p53 and MDM2 stability. Oncogene 20: 1267–1273.
35. Shimosu H, Borch JR, Smith AJ, Dorman D, Wallace M, et al. (2002) The conformationally flexible S9–S10 linker region in the core domain of p53 contains a novel MDM2 binding site whose mutation increases ubiquitination of p53 in vivo. J Biol Chem 277: 28446–28450.
36. Bothner B, Lewis WS, DiGiammarino EL, Weber JD, Rodner S, et al. (2001) Defining the molecular basis of Arf and Hdm2 interactions. J Mol Biol 314: 263–277.
37. Lohrum MA, Ahscroft M, Kubbutat MH, Vouuden KH (2000) Contribution of two independent MDM2-binding domains in p14(ARF) to p53 stabilization. Curr Biol 10: 539–542.
38. Dai MS, Zenz SX, Jin Y, Sun XX, David L, et al. (2004) Ribosomal protein L23 activates p53 by inhibiting MDM2 function in response to ribosomal perturbation but not to translation inhibition. Mol Cell Biol 24: 7654–7660.
39. Jin A, Inahana K, O'Keefe K, Zhang Y (2004) Inhibition of HDM2 and activation of p53 by ribosomal protein L23. Mol Cell Biol 24: 7669–7680.
40. Zhang Y, Wolf GV, Bhat K, Jin A, Allis T, et al. (2005) Ribosomal protein L11 negatively regulates oncoprotein MDM2 and meditates a p53-dependent ribosomal-stress checkpoint pathway. Mol Cell Biol 25: 8902–8912.
41. Takagi M, Absalon MJ, McLure KG, Kastan MB (2005) Regulation of p53 translation and induction after DNA damage by ribosomal protein L26 and nucleolin. Cell 123: 49–63.
42. Zhu Y, Poyurovsky MV, Li Y, Bidnerman L, Stahl J, et al. (2009) Ribosomal protein S7 is both a regulator and a substrate of MDM2. Mol Cell 35: 316–326.
43. Roger L, Gadea G, Roux P (2006) Control of cell migration: a tumour suppressor function for p53? Biol Cell 98: 141–152.
44. Ridley AJ, Schwartz MA, Burridge K, Firtel RA, Ginsberg MH, et al. (2003) Cell migration: integrating signals from front to back. Science 302: 1704–1709.
45. Zuccherio JB, Coutts AS, Quindan ME, Thangue NB, Mullins RD (2009) p53-cofactor JMY is a multifunctional actin nucleation factor. Nat Cell Biol 11: 451–459.
46. Coutts AS, Weston L, La Thangue NB (2009) A transcription co-factor integrates cell adhesion and motility with the p53 response. Proc Natl Acad Sci U S A 106: 19872–19877.